Part II · The Neurochemical Temperament Map Draft
Chapter 9
Serotonin
Harm, Patience, Restraint, and Social Norms
Serotonin may be the neurotransmitter most damaged by its own public relations. For decades it was described as the chemistry of happiness, with depression imagined as the consequence of having too little. The simplicity was memorable and scientifically misleading.
The serotonin system contains many receptor families with different distributions and effects. Acute pharmacological changes can differ from chronic ones. The same serotonergic intervention can alter anxiety, appetite, sexual function, patience, emotional intensity, sleep, social processing, and gastrointestinal physiology. There is no single psychological variable called “serotonin level” that captures this.
Yet the system remains highly relevant to personality because several of its functions sit near enduring human trade-offs: immediate reward versus delayed consequence, impulse versus restraint, punishment versus exploration, emotional reactivity versus recovery, dominance versus accommodation, and individual desire versus social norm.
An early version of the personality-pharmacology framework associated stronger serotonergic influence with patience, harm avoidance, behavioral restraint, emotional resilience, and greater sensitivity to social rules. Lower influence was associated, depending on context, with impulsivity, aggression, unstable affect, or reduced behavioral inhibition. At the opposite extreme, excessive or poorly targeted serotonergic influence was imagined as potentially contributing to passivity, rigidity, emotional flattening, or overconformity.
This map should not be treated as one axis. It is better understood as a collection of hypotheses about control operations.
Patience is one candidate. To choose a delayed reward over an immediate one, a system must value future outcomes sufficiently and tolerate the discomfort of waiting. Punishment sensitivity is another. To suppress an action because it may produce harm, the anticipated negative outcome must carry enough weight. Affective recovery is another: emotional systems need to return toward baseline after activation. Social behavior adds further complexity because restraint can reflect empathy, fear of exclusion, learned rules, hierarchy, or genuine long-term cooperation.
The word restraint therefore needs care. Restraint can be adaptive self-control, but it can also be inhibition that prevents a person from acting according to their values. The socially anxious person who cannot speak is restrained. The impulsive person who cannot wait is insufficiently restrained. A useful intervention may move each in opposite directions.
This is one reason the subjective effect of serotonergic medication is ethically interesting. For some people, reducing emotional intensity creates space to act. Thoughts that once felt urgent become tolerable. Rejection becomes survivable. Anger becomes less commanding. Rumination loses force. The person experiences the change as freedom.
Another person may experience a similar reduction in intensity as loss. Love feels flatter. Sexual desire weakens. Ambition becomes less urgent. Sadness is reduced, but so is emotional vividness. If a treatment lowers suffering by lowering the amplitude of experience, has it restored the person or changed them?
There is no universal answer because the effect interacts with baseline and values.
Chronic treatment further complicates interpretation. An acute increase in synaptic serotonin is not the same biological state as weeks of treatment after receptor and network adaptation. It is therefore a mistake to infer the function of the baseline serotonin system from one acute drug effect or to treat chronic SSRI response as a direct assay of “serotonergic personality”.
The social dimension is even more speculative but potentially important. Human morality and cooperation depend partly on emotional responses to harm, fairness, reciprocity, exclusion, guilt, aggression, and social rules. If serotonergic systems influence patience, aversive processing, impulse restraint, and social behavior, then pharmacological changes could alter the felt force of moral intuitions.
This should not be translated into “serotonin makes people moral”. Greater conformity can preserve cooperation or suppress dissent. Lower aggression can reduce harm or reduce the willingness to resist exploitation. Increased patience can improve judgment or support unhealthy endurance. A biological system can shift social strategy without supplying a moral verdict.
The empirical test of the personality hypothesis is not whether serotonin correlates with a broad trait score once. It is whether specific baseline functions such as harm avoidance, impulse control, temporal discounting, affective persistence, or social threat predict how serotonergic perturbations alter behavior over time. Receptor-specific effects should matter. Region should matter. Baseline symptoms should matter. The same intervention should not be expected to move every person along the same psychological dimension.
The deepest lesson is similar to the dopamine chapter but points in a different direction. A person’s sense of character partly emerges from what feels urgent and what can be resisted. Change the weighting of harm, delay, emotion, and social consequence, and the person’s behavioral policy changes.
That change may be experienced as treatment, blunting, maturity, passivity, relief, or alienation. The biology does not choose the interpretation.
Noradrenaline adds a third control problem. Even if reward and restraint were held constant, people would still differ in how strongly the world mobilizes them. That is the terrain of arousal and vigilance.